LFLorna R. Fiedler

Lorna R. Fiedler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lorna R. Fiedler has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • Ester Khin

    Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore

    2 shared publications
  • Evie Maifoshie

    Imperial College London

    2 shared publications
  • Johannes A. Eble

    Centre for Molecular Medicine; Vascular Matrix Biology; Excellence Cluster Cardiopulmonary System; Frankfurt University Hospital; Frankfurt, Germany

    2 shared publications
  • Michael D. Schneider

    British Heart Foundation Centre of Research Excellence, National Heart and Lung Institute, Imperial College London, London, UK

    2 shared publications
  • Nicole S J Ko

    Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore, Singapore

    2 shared publications
  • Allison B. Faber

    Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany

    1 shared publication

Latest Publications

  • Titin truncations lead to impaired cardiomyocyte autophagy and mitochondrial function in vivo

    by Jin Zhou, Benjamin Ng, Nicole S J Ko, Lorna R Fiedler, Ester Khin, Andrea Lim, Norliza E Sahib, Yajun Wu, Sonia P Chothani, Sebastian Schafer, et al.

    Titin-truncating variants (TTNtv) are the most common genetic cause of dilated cardiomyopathy. TTNtv occur in ~1% of the general population and causes subclinical cardiac remodeling in asymptomatic carriers. In rat models with either proximal or distal TTNtv, we previously showed altered cardiac metabolism at baseline and impaired cardiac function in response to stress. However, the molecular mechanism(s) underlying these effects remains unknown. In the current study, we used rat models of TTNtv to investigate the effect of TTNtv on autophagy and mitochondrial function, which are essential for maintaining cellular metabolic homeostasis and cardiac function. In both the proximal and distal TTNtv rat models, we found increased levels of LC3B-II and p62 proteins, indicative of diminished autophagic degradation. The accumulation of autophagosomes and p62 protein in cardiomyocytes was also demonstrated by electron microscopy and immunochemistry, respectively. Impaired autophagy in the TTNtv heart was associated with increased phosphorylation of mTOR and decreased protein levels of the lysosomal protease, cathepsin B. In addition, TTNtv hearts showed mitochondrial dysfunction, as evidenced by decreased oxygen consumption rate in cardiomyocytes, increased levels of reactive oxygen species and mitochondrial protein ubiquitination. We also observed increased acetylation of mitochondrial proteins associated with decreased NAD+/NADH ratio in the TTNtv hearts. mTORC1 inhibitor, rapamycin, was able to rescue the impaired autophagy in TTNtv hearts. In summary, TTNtv leads to impaired autophagy and mitochondrial function in the heart. These changes not only provide molecular mechanisms that underlie TTNtv-associated ventricular remodeling but also offer potential targets for its intervention.


  • Top Cited Papers
    Open Access

    Titin-truncating variants affect heart function in disease cohorts and the general population

    by Sebastian Schafer, Antonio de Marvao, Eleonora Adami, Lorna R Fiedler, Benjamin Ng, Ester Khin, Owen J L Rackham, Sebastiaan van Heesch, Chee J Pua, Miao Kui, et al.

    Stuart Cook and colleagues study the role of TTN (titin)-truncating variants using a combination of heart physiology experiments in rats and genomic analysis in humans. Their data show that TTN variants are associated with a range of cardiac phenotypes in healthy individuals and in patients with dilated cardiomyopathy. Titin-truncating variants (TTNtv) commonly cause dilated cardiomyopathy (DCM). TTNtv are also encountered in ∼1% of the general population, where they may be silent, perhaps reflecting allelic factors. To better understand TTNtv, we integrated TTN allelic series, cardiac imaging and genomic data in humans and studied rat models with disparate TTNtv. In patients with DCM, TTNtv throughout titin were significantly associated with DCM. Ribosomal profiling in rat showed the translational footprint of premature stop codons in Ttn, TTNtv-position-independent nonsense-mediated degradation of the mutant allele and a signature of perturbed cardiac metabolism. Heart physiology in rats with TTNtv was unremarkable at baseline but became impaired during cardiac stress. In healthy humans, machine-learning-based analysis of high-resolution cardiac imaging showed TTNtv to be associated with eccentric cardiac remodeling. These data show that TTNtv have molecular and physiological effects on the heart across species, with a continuum of expressivity in health and disease.


  • Open Access

    Breaking Female Hearts: The Gender Gap in Cardiovascular Research

    by Lorna R. Fiedler

    Cardiovascular disease is the biggest killer of both men and women, causing 17.5 million deathscombined in 2012,1 which is expected to rise to 23.4 million by 2030.2 The leading cause ofdeath in both sexes is ischemic heart disease, with hypertensive heart disease also appearing inthe top ten and vascular complications the majority of the remainder.1 Notably, mortality ratesare increasing more rapidly in younger women compared to men.3 Given these observations, itmight be expected that our knowledge of the cardiovascular system and treatment of its disorderswould be based on studies performed on biological material and organisms of both maleand female origin, in fairly equal proportions. However, this is simply not the case. In biomedicalresearch, many publications do not specify the sex of the animals (presumably the readershould assume male), and where sex is specified the majority focus on males.4 In addition,drug studies are conducted mainly on males.5 Equal representation of men and women is alsolacking in many large-scale clinical trials4,6; somewhat surprising given that women represent arather significant proportion of patients undergoing treatment in the clinic.


  • Open Access

    Pharmacological Agents in the Clinic: Trial and Error

    by Lorna R. Fiedler

    Following an explosion of molecular and cellular research in the last 50 years, thestudy of specific molecular targets in the context of heart failure has generated much excitement.With the incidence of heart failure rising worldwide, new pharmacological agents areeagerly anticipated as a key tool with the potential for significant impact. In this regard, theresults of the keenly awaited Does Cyclosporine Improve Clinical Outcome in ST ElevationMyocardial Infarction Patients (CIRCUS) trial have just been made available. Despite a substantialprogramme of supporting experimental and preclinical evidence however, the resultshave proved negative. This is of great disappointment to the clinical and scientific community.Here, this is discussed in the context of previous studies and future directions explored.


  • Open Access

    Cardiovascular Research: Past, Present and Future

    by Lorna R. Fiedler

    Cardiovascular disease remains a leading cause of death and significant burden onhealthcare systems worldwide. While interventional and preventative medicine has considerablychanged the face of clinical practice, at the molecular level, treatment has not altered inrecent decades and is still directed towards alleviating symptoms or mitigating the underlyingcause rather than regenerating damaged heart muscle. This is surprising, given the explosion ofresearch in this area in the 1970’s, and the fact that research output has continued to increaseexponentially. With the incidence of heart failure on the rise, a trend predicted to continue, itis imperative that treatment strategies are improved. The development and adoption of molecularinterventions might therefore present the most fruitful avenue in providing the greatestimpact on mortality rates. This commentary aims to reflect on the earliest documented studiesof human cardiovascular physiology, to surgical interventions in the 12th, to the first molecularstudies in the 20th, to current pharmacological treatments. With this knowledge in mind, thefuture of molecular approaches in treating heart failure and cardiovascular conditions will beconsidered.


  • 157 Approaches for Pharmacological Inhibition of Cardiac Cell Death: MAP4K4 as a Therapeutic Target

    by Lorna Fiedler, Katie Chapman, Evie Maifoshie, Caroline Low, Catherine Tralau-Stewart, Michael Schneider

    Introduction Cell death plays a causal role in heart failure, and its inhibition poses a promising approach that has not been thoroughly explored. In past approaches to target discovery, clinical failures have reflected deficiencies in mechanistic understanding, and failure to translate laboratory findings to a human setting. We previously identified MAP4K4/HGK as an activator of the TAK1 - JNK pathway in cardiac cell death, whose inhibition by dominant-negative mutations or shRNA knockdown confers protection in cultured rat neonatal cardiomyocytes. Methods Compound activity against MAP4K4 recombinant purified kinase domain was carried out by HTRF Transcreener ADP assay (Cisbio), knockdown of MAP4K4 was achieved by virus-mediated gene transfer of shRNAmirs into human induced pluripotent stem cell (iPSC)-derived cardiomyocytes. Selectivity was assessed against a panel of 140 human kinases (Dundee, MRC protein phosphorylation and ubiquitination unit). Cell death was assessed by hypodiploid DNA content, Draq7 uptake and Caspase 3 activity. Results Firstly confirming the relevance of MAP4K4 in a human setting, shRNAmir-mediated knockdown was protective against H202-induced cardiomyocyte cell death in human iPSC-derived cardiomyocytes. To address this therapeutic potential, we initiated a small molecule drug discovery programme by first screening a library of known kinase inhibitors for activity against recombinant MAP4K4 kinase domain. Hits with pIC50 > 7 (series 1) that shared similar features of charge distribution were used to generate a consensus pharmacophore model for inhibition of MAP4K4. Virtual interrogation of a database of more than one million compounds identified novel compounds fitting this model. The top 40 ranked compounds were tested for activity against MAP4K4 and the most potent from each of two chemical series (series 2) taken forward. Series 2 had much improved selectivity (only 3–5 of 141 kinases inhibited > 50% at 1 M) over both series 1 and two small molecule inhibitors described by Pfizer. In addition, series 2 were not toxic to cardiomyocytes up to 10 M. Importantly both compounds from series 2 showed protection against H202- or C2-ceramide mediated cell death in rat neonatal cardiomyocytes. Conclusions Thus we have obtained promising lead compounds for optimisation and mechanistic studies in both murine and human models, and shown that inhibition of MAP4K4 in vitro , whether by knockdown of expression or pharmacological inhibition is protective against cell death in cardiomyocytes. MAP4K4 is therefore a potential target for pharmacological inhibition of cell death in cardiac disease.


  • T 1 Mapping Detects Pharmacological Retardation of Diffuse Cardiac Fibrosis in Mouse Pressure-Overload Hypertrophy

    by Daniel J. Stuckey, Sara J. McSweeney, May Zaw Thin, Josef Habib, Anthony N. Price, Lorna R. Fiedler, Willy Gsell, Sanjay K. Prasad, Michael D. Schneider

    Background—: Diffuse interstitial fibrosis is present in diverse cardiomyopathies and associated with poor prognosis. We investigated whether magnetic resonance imaging-based T 1 mapping could quantify the induction and pharmacological suppression of diffuse cardiac fibrosis in murine pressure-overload hypertrophy. Methods and Results—: Mice were subjected to transverse aortic constriction or sham surgery. The angiotensin receptor blocker losartan was given to half the animals. Cine-magnetic resonance imaging performed at 7 and 28 days showed hypertrophy and remodeling and systolic and diastolic dysfunction in transverse aortic constriction groups as expected. Late gadolinium-enhanced magnetic resonance imaging revealed focal signal enhancement at the inferior right ventricular insertion point of transverse aortic constriction mice concordant with the foci of fibrosis in histology. The extracellular volume fraction, calculated from pre- and postcontrast T 1 measurements, was elevated by transverse aortic constriction and showed direct linear correlation with picrosirius red collagen volume fraction, thus confirming the suitability of extracellular volume fraction as an in vivo measure of diffuse fibrosis. Treatment with losartan reduced left ventricular dysfunction and prevented increased extracellular volume fraction, indicating that T 1 mapping is sensitive to pharmacological prevention of fibrosis. Conclusions—: Magnetic resonance imaging can detect diffuse and focal cardiac fibrosis in a clinically relevant animal model of pressure overload and is sensitive to pharmacological reduction of fibrosis by angiotensin receptor blockade. Thus, T 1 mapping can be used to assess antifibrotic therapeutic strategies.


  • Mouse Models of Heart Failure

    by Lorna R. Fiedler, Evie Maifoshie, Michael D. Schneider


  • 12 MAP4K4 as a Therapeutic Target in Cardiomyocyte Death: Novel inhibitors Identified through Pharmacophore Modelling and Virtual Screening

    by L R Fiedler, K Chapman, W Guo, S Kanaganayagam, C Low, C Traulau-Stewart, M D Schneider

    Ratonale: Though reperfusion therapies have transformed treatment of myocardial infarction, no established treatments directly address the problem of cardiac cell death. At the level of organ function, attenuating acute or chronic cell death would preserve cardiac pump function and suppress progression to heart failure. We previously identified MAP4K4/HGK as an activator of the TAK1 – JNK pathway in cardiac cell death, whose inhibition by dominant-negative mutations or shRNA knockdown confers protection in culture. To address this therapeutic potential and further dissect the mechanisms by which MAP4K4 mediates cardiomyocyte death, we initiated a small molecule discovery programme. Results: An in-house library of 2000 compounds was screened for inhibition of recombinant human MAP4K4 kinase domain. Eight showed a pIC50 > 5, and the top four were taken forward. Hits were analysed by 3D field point modelling (Cresset) to identify features of similar charge distribution. Three inhibitors fitted a consensus pharmacophore model, used to interrogate 2.5 M structures in silico, from which 40 were tested for inhibition of MAP4K4. Selectivity of the top two was tested both against a panel of >140 human kinases and against the kinome in situ, using cell lysates. Relative to the only known MAP4K4 inhibitors, these exhibited equal potency (IC50 35-100 nM) but greater specificity (3-5 kinases inhibited >50% at 1 uM) and lack of toxicity in cardiomyocytes. Conclusions: We have successfully employed pharmacophore modelling and virtual screening to leverage an initial screen for novel MAP4K4 inhibitors, and obtained promising lead compounds for optimisation and experimental studies.


  • The ADMA/DDAH Pathway Regulates VEGF-Mediated Angiogenesis

    by Lorna R Fiedler, Tiziana Bachetti, James Leiper, Ian Zachary, Lihua Chen, Thomas Renné, Beata Wojciak-Stothard

    Objectives— Asymmetrical dimethylarginine (ADMA) is a nitric oxide synthase (NOS) inhibitor and cardiovascular risk factor associated with angiogenic disorders. Enzymes metabolising ADMA, dimethylarginine dimethylaminohydrolases (DDAH) promote angiogenesis, but the mechanisms are not clear. We hypothesized that ADMA/DDAH modifies endothelial responses to vascular endothelial growth factor (VEGF) by affecting activity of Rho GTPases, regulators of actin polymerization, and focal adhesion dynamics. Methods and Results— The effects of ADMA on VEGF-induced endothelial cell motility, focal adhesion turnover, and angiogenesis were studied in human umbilical vein endothelial cells (HUVECs) and DDAH I heterozygous knockout mice. ADMA inhibited VEGF-induced chemotaxis in vitro and angiogenesis in vitro and in vivo in an NO-dependent way. ADMA effects were prevented by overexpression of DDAH but were not associated with decreased proliferation, increased apoptosis, or changes in VEGFR-2 activity or expression. ADMA inhibited endothelial cell polarization, protrusion formation, and decreased focal adhesion dynamics, resulting from Rac1 inhibition after decrease in phosphorylation of vasodilator stimulated phosphoprotein (VASP). Constitutively active Rac1, and to a lesser extent dominant negative RhoA, abrogated ADMA effects in vitro and in vivo. Conclusion— The ADMA/DDAH pathway regulates VEGF-induced angiogenesis in an NO- and Rac1-dependent manner. The endogenous NO synthase inhibitor and cardiovascular risk factor ADMA inhibits angiogenesis. We show for the first time that ADMA inhibits VEGF-induced endothelial cell motility and angiogenesis by modulating NO-dependent Rho GTPase activity. Further, normal angiogenic responses to VEGF are restored by overexpression of DDAH or active Rac1.